PSUN199 SGLT2-Inhibitor Prescription Rates in Individuals with Diabetic Nephropathy at a Teaching Outpatient Clinic

INTRODUCTION: Type 2 diabetes mellitus is one of the leading causes of kidney failure worldwide. According to the CREDENCE trial published in June 2019, SGLT2 inhibitors have significant benefits in renal outcomes even in individuals with more advanced diabetic kidney disease specifically in terms of slowing disease progression. The American Diabetes Association (ADA) recommends using SGLT2-Inhibitor for patients with type 2 diabetes and diabetic kidney that have GFR>=30 ml/min/1.73 m(2) and urinary albumin >300 mg/g creatinine. However, we hypothesize that SGLT2-inhibitor is under-prescribed in those individuals. The aim of this study is to assess the rate of SGLT2-inhibitor prescription in those individuals. METHODS: We performed a retrospective observational study of individuals seen at an outpatient multispecialty medical building at a tertiary teaching hospital from February 2020 to July 2021. We chart audited 482 individuals seen at least 3 times at the clinic with the diagnosis of diabetes on their electronic medical record. We included only individuals with type 2 diabetes, who have GFR >=30 ml/min/1.73 m(2) and urinary albumin>300 mg/g creatinine. We performed an analysis looking at the rate of SGLT2-inhibitor prescription in the clinic. RESULTS: A total of 36 individuals were included in our final analysis with mean age [standard deviation] of 63 [9.9], 72.2% Male, 80.5% African American, BMI of 33.37 [8.0], HbA1C of 8.9 [2.4], Albumin/creatinine 1395.7 mg/g [1432.3], GFR 53.92 ml/min/1.73 m(2) [17.5] and 97.2% had health insurance. Only 7 individuals (19.4%) of the qualified cohort were prescribed SGLT2-inhibitor at the clinic. CONCLUSION: SGLT2-inhibitor is under-prescribed at the clinic, with only 19.4% of the qualified cohort being prescribed SGLT2-inhibitor. Although the cost of the medication is likely a confounding factor however this could also be due to a knowledge gap among providers about the standards of diabetes care guidelines. We plan to take steps to create awareness regarding the under-prescription of SGLT2-inhibitor among providers and provide educational interventions to help improve the prescription rate of SGLT2-inhibitor and potentially decrease the rate of decline in kidney function in our patient population. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m.